On May 10, 2020 Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, reported that latest clinical data of the company’s drug candidates, including the MDM2-p53 inhibitor APG-115, novel Bcl-2/Bcl-xL dual inhibitor APG-1252, and IAP inhibitor APG-1387, will be presented in three poster discussions and a poster at the 2020 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Ascentage Pharma, MAY 10, 2020, View Source [SID1234557437]). Because of concerns about the current coronavirus (COVID-19) pandemic, this year’s annual meeting will be held in a virtual format from May 29 through May 31, 2020.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ASCO (Free ASCO Whitepaper) Annual Meeting is the most authoritative meeting in the oncology space. The purpose of this meeting is to disseminate premier scientific research and cutting-edge treatment approaches in oncology to the world.
"We are excited to present the clinical advances of three of our drug candidates," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "Through these results, Ascentage Pharma is demonstrating its capabilities of global clinical development in apoptosis. We are striving to offer more treatment options for patients with unmet medical needs."
Four posters will be presented at ASCO (Free ASCO Whitepaper)20, including:
Poster Discussion Sessions
Phase Ib study of a novel, small-molecule MDM2 inhibitor APG-115 combined with pembrolizumab in U.S. patients with metastatic solid tumors
Time: May 29th, 8:00–11:00am, EST
Abstract: #3512
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors
Time: May 29th, 8:00–11:00am, EST
Abstract: #3509
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Phase Ib study of a novel bivalent IAP antagonist APG-1387 in combination of pembrolizumab for patients with advanced solid tumors
Time: May 29th, 8:00–11:00am, EST
Abstract: #3508
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Poster Session
Phase I study results of APG-115, a MDM2-p53 antagonist, in Chinese patients with advanced liposarcoma and other solid tumors
Time: May 29th, 8:00–11:00am, EST
Abstract: #11542
Session: Sarcoma